XALKORI is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1) This indication is based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of XALKORI (crizotinib) Capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the XALKORI (crizotinib) Capsules medicine cost price in India.
The order for XALKORI (crizotinib) Capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Crizotinib is a type of targeted cancer drug. It is a treatment for advanced non small cell lung cancer (NSCLC). It is for NSCLC that has changes in either a gene called anaplastic lymphoma kinase (ALK) or ROS1. Your doctor checks your cancer for these gene changes.
XALKORI® (crizotinib) Capsules, oral Initial U.S. Approval: August 2011
Generic Name: crizotinib
XALKORI Capsules: 250 mg and 200 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand XALKORI (crizotinib) Capsules on prescription and Import License in Patient's Name only.
For overseas patients, XALKORI (crizotinib) Capsules can be made available in Send your enquiry to find XALKORI (crizotinib) Capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For XALKORI (crizotinib) Capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Dr. Saxena on Treatment Options in ALK+ NSCLC For More Details
Xalkori-Alecensa sequential therapy advantageous in duration of treatment
Dated: Sunday, Mar 11, 2018